CSPC Pharmaceutical Group Ltd saw its shares surge over 5% on Monday after announcing an exclusive licensing agreement with Jiangsu Alphamab for the development and commercialization of a novel cancer drug candidate in mainland China.
Under the agreement, CSPC PHARMA has secured the rights to develop and commercialize JSKN003, a potential best-in-class antibody-drug conjugate targeting HER2-positive solid tumors. In addition to an upfront payment, Jiangsu Alphamab will also receive milestone payments and royalties on any future sales of the drug in China.
Investors appear to be excited about the deal, which will bolster CSPC PHARMA's oncology pipeline with a promising new therapeutic candidate. JSKN003 has shown promising efficacy and safety data in early clinical trials, and the market for HER2-targeted drugs in China is expected to grow significantly in the coming years.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。